"Boom! Medpace (MEDP) just dropped a mic with killer earnings and clinical trial hype 🎤. The stock rocketed 40%—RSI’s screaming overbought at 85 (🚨), but those WMAs are doing the cha-cha upward. Volume? Explosive. This feels FOMO-tastic, but tread carefully—this rocket might need a breather. Chart’s wild, but news trumps all. Short-term: ride the wave (BUY), but keep a finger near the exit. #MEDPMoonMission 🌙"

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc. MEDP: 548.12 USD

Bullish views